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Abstract
Summary Health claims for food products in Europe are
permitted if the nutrient has been shown to have a
beneficial nutritional or physiological effect. This paper
defines health claims related to bone health and provides
guidelines for the design and the methodology of clinical
studies to support claims.
Introduction Regulation (EC) no. 1924/2006 on nutrition
and health claims targeting food products was introduced in
Europe stating that health claims shall only be permitted if
the substance in respect of which the claim is made has
been shown to have a beneficial nutritional or physiological
effect. The objective of this paper is to define health claims
related to bone health and to provide guidelines for the
design and the methodology of clinical studies which need
to be adopted to assert such health claims.
Methods Literature review followed by a consensus discus-
sion during two 1-day meetings organized by the Group for
the Respect of Ethics and Excellence in Science (GREES).
Results The GREES identified six acceptable health claims
related to bone health based on the potential of food
products to show an effect on either the bioavailability of
calcium or osteoclast regulatory proteins or bone turnover
markers or bone mineral density or bone structure or
fracture incidence. The GREES considers that well-
designed human randomized controlled trial on a relevant
outcome is the best design to assess health claims. The
substantiation of health claim could also be supported by
animal studies showing either an improvement in bone
strength with the food product or showing the relationship
between changes induced by the food product on a
surrogate marker and changes in bone strength.
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Conclusion The consensus reached is that the level of
health claim may differ according to the surrogate endpoint
used and on additional animal studies provided to support
the claim.
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Introduction
More and more food products bear health claims. The
skepticism of consumers regarding functional foods is
mainly due to doubts over the veracity of health claims
and in the poor and often inadequate control of their
claimed properties. It is important that health claims should
provide genuine information to help consumers choose
healthy diets. Consequently, claims should be supported by
a sound and sufficient body of scientific evidence to
substantiate them and be reinforced by specific consumer
education.
Since health claims on food products are increasingly
recognized to be important, they are being legally regulated
in more and more countries around the world [1]. Although
there is a general scientific consensus on how to substan-
tiate health claims on food [2], there is no agreement on the
specific approaches and indicators that can be used in
different fields. Various jurisdictions have developed
systematic approaches for reviewing scientific data linking
food products and health with the objective of identifying
the threshold of scientific evidence needed to substantiate
an authoritative statement to the general public in the form
of a label claim for a given marketed food product. In
Europe, a regulation on nutrition and health claims made on
foods was introduced in 2007. This regulation provides
opportunities for the use of health claims on foods in
Europe, including reduction of disease risk [3]. According
to Regulation EC 1924/2006, the use of nutrition and health
claims shall only be permitted if the substance in respect of
which the claim is made has been shown to have a
beneficial nutritional or physiological effect. A community
list of permitted and rejected claims has been established
and made available to the public (http://ec.europa.eu/food/
food/labellingnutrition/claims/community_register/health_
claims_en.htm).
The regulation defines a health claim in general as “any
claim that states, suggests or implies that a relationship
exists between a food category, a food or one of its
constituents and health.” All claims are addressed in
Articles 13 and 14 of the Regulation EC 1924/2006
(Table 1).
In the context of health claims in foods, bone health is of
potential interest as it is a major public health problem, at
least in Western countries [4]. Up to 60% of the variance in
bone mass is determined by genetic factors. Environmental
factors account for the remainder, including nutritional
intake and lifestyle habits throughout life [5, 6].
In the field of bone health, there are no scientifically
based definitions of health claims and no uniform recom-
mendations of the preferred study and/or methodology,
even though some preparatory work had been done before
the introduction of the European regulations [4]. The
objective of this paper was to define the relevant biomarker
for bone health and to provide recommendations for the
design and the methodology of clinical studies which need
to be fulfilled to assert claims related to bone health. The
intent was to aid regulatory authorities in defining claims
and assessing scientific evidence used to support those that
relate to bone health. By establishing common criteria for
these assessments, it is hoped that these recommendations
will lead to harmonization of the requirements for scientific
substantiation of claims worldwide.
Methods
Two 1-day meetings were organized by the Group for the
Respect of Ethics and Excellence in Science (GREES). This
non-for-profit organization has expertise in literature re-
search and consensus meetings. The meetings were
attended by academic scientists with expertise in the field
of bone health or nutrition, members of regulatory
authorities as well as industrialists with interests in health
claims relating to bone. The objective of the first day of the
meeting was to critically review the current literature in the
field of health claims related to bone and to discuss the
needs and problems to assert such claims. The objective of
the second day was to reach consensus on scientifically
acceptable health claims related to bone and to provide
guidelines for the design and the methodology of clinical
studies which need to be adopted to assert such health
claims.
A literature search, using Medline database up to August
2010, was performed using keywords including health
claims, nutrition, bone, osteoporosis, clinical study meth-
odology, surrogate endpoint. A selection of relevant papers
was made by OB, RR, and JYR.
Results
The GREES panel considers that clinical data in humans
are indispensable, and that health claims cannot be accepted
solely on the basis of animal data. However, as discussed
below, animal studies can give important information not
available in humans and can provide data for the general-
ization of results obtained in a specific tested population to
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a larger group. Thus, different levels of heath claims should
be considered based both on the endpoint used and on the
information provided by animal studies.
Pre-clinical models
A variety of invasive and non-invasive techniques can be
used to provide relevant endpoints [4, 7], including
bioavailability studies, microarray or PCR analysis of
modulated genes, histomorphometry, culture of bone
forming or bone resorbing cells ex vivo, exposure to
primary cell cultures to plasma harvested from treated
animals, the chemistry and biochemistry of bone tissue,
the assessment of biochemical indices of skeletal turnover
in blood and urine, metabolic balance of calcium com-
bined with radioactive calcium kinetics, radiogrammetry
of bone radiographs, neutron activation for whole body
calcium, dual x-ray absorptiometry (DXA), and the
assessment of bone strength [8]. The latter endpoint is
considered to be the most relevant in the field of bone
health claims. Bone strength reflects both bone density
and bone quality. Bone quality depends on bone architec-
ture, mineralization, turnover, and accumulation of micro-
damage. Therefore, the assessment of bone health would
benefit from the measurement of bone strength in vivo.
No validated non-invasive tools capable of measuring
bone strength in vivo are available to date. However,
biomechanical tests of resistance to fracture provide an
objective measure of overall bone strength. The three
main types of biomechanical tests for bone strength are
bending, torsional, and compression tests [9]. It is
considered that both long bones and vertebral bodies
should be tested since they may be differentially affected
by food products.
Besides the assessment of a direct effect of the food
product on bone strength, two other aims of animal data
could be to better understand the mechanism of action of
the food product or to validate surrogate variables used in
human animal data to see if these variables reflect bone
strength.
Key criteria of suitable/acceptable animal studies are:
➢to deliver the food product in the manner in which it
will be delivered in a human setting;
➢to utilize a site of delivery and/or assessment site that
is as closely matched as possible to the settings in
which it will be used;
➢to utilize an animal that provides a metabolic
background and physiological responsiveness compa-
rable to humans;
➢to utilize a formulation of active agent that has the
same composition, release, retention, and degradation
properties as the formulation that will be used in
humans.
Acceptable health claims in human bone health
The GREES panel considers that six different health claims
could be accepted for an effect of food products on bone
health. However, as already used by the European Food and
Safety Authority, different wording to reflect the level of
evidence of the effect could be used depending on the effect
that is (always), may (demonstrated only under certain
circumstances) or might be (logically expected benefit from
physiology but yet not demonstrated) beneficial for bone
health.
1. Improvement of calcium bioavailability
Calcium bioavailability may be defined as the
proportion of calcium in foods which is absorbed and
utilized for normal metabolic functions. In addition
to the amount of calcium in the diet, the fractional
absorption of dietary calcium in food and its
retention in the body are also a factor that determines
the availability of calcium for bone development and
maintenance of bone health [10, 11]. Many methods
can be used to assess bioavailability (i.e., classical and
isotopic balances, urinary excretion, isotope labeling
in the urine, plasma, and bones) [12]. The group
considers that an increase in bioavailability is not
Table 1 Claims addressed in articles 13 and 14 of the Regulation EC 1924/2006
Article 13 Article 14
Article 13.1 Article 13.5
Referring
to
the role of a nutrient or other
substance in growth, development
and the functions of the body
the role of a nutrient or other substance in growth,
development and the functions of the body based on
newly developed scientific evidence and/or which
include a request for the protection of proprietary
data.
the reduction of disease risk and
claims relating to children's
development and health
Application
based on
generally accepted scientific
evidence
submission of an extensive scientific dossier submission of an extensive
scientific dossier
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beneficial if not accompanied by calcium retention in
the body. A food product with an effect on calcium
bioavailability with or without calcium retention data,
unless associated with appropriate animal studies
would not fulfill a claim related to article 14.
However, food products that show an effect on
bioavailability and calcium retention could have an
article 13 claim: “X increases calcium absorption” or
“X increases calcium bioavailability”.
2. Maintenance of bone metabolism (through an effect on
osteoclast regulatory proteins)
The transition of osteoclast precursors to mature
osteoclasts that are capable of resorbing bone is tightly
regulated by osteoclast regulatory proteins that either
affect the differentiation and proliferation of osteoclast
precursors into mature osteoclasts or are involved in the
coupling between osteoblasts and osteoclasts [13].
Markers of osteoclastogenesis include receptor activa-
tor of nuclear factor kappa-B ligand and osteoprote-
gerin, whereas markers of osteoclast number include
tartrate-resistant acid phosphatase and cathepsin K.
These proteins contribute to bone metabolism but are
not yet strongly associated with elements of bone
strength. A food product with an effect on osteoclast
regulatory proteins, unless supported by animal studies
(see next BMD and BTM sections) would not fulfill a
claim related to article 14. The product, however, might
have the label under the article 13: “X contributes to the
maintenance of bone metabolism”.
3. Maintenance or changes in bone turnover marker
A determinant of bone strength that is not assessed
by bone mineral density (BMD) is the rate of bone
remodeling. Depending upon their origin, bone turn-
over markers (BTMs) are classified as indices of bone
resorption or formation [14–17]. The rate of bone
resorption and formation can be estimated by assays
that measure the serum concentration or urinary
excretion of different target molecules specific to these
cellular processes. GREES panel recommends the
inclusion of reference markers of bone formation
(serum procollagen type I N propeptide, s-PINP) and
resorption (serum C-terminal cross-linking telopeptide
of type I collagen, s-CTX) in keeping with the
recommendations of the International Osteoporosis
Foundation [18]. A food product with a positive BTM
balance might have the claim: “X maintains normal
bone remodeling that could contribute to the normal
structure and function of bones” or “X increases
markers of bone formation that could contribute to the
normal structure and function of bones” or “X
decreases markers of bone resorption that could
contribute to the normal structure and function of
bones”.
As in the case of BMD, BTMs are only indicators of
fracture risk, but the change in BTM induced by a
product is not necessarily associated with a change in
fracture risk or bone strength. In this regard, animal
models are useful to assess if changes in BTMs due to
the intake of the food product are associated with an
increase in bone strength. A food product with an effect
on BTMs together with animal studies that showed
improved bone strength or a relationship between
changes in BTMs induced by the food product and
bone strength could have the claim: “X contributes to
the maintenance of normal bone remodeling (or
increases bone formation or decreases bone resorption)
that is associated with bone strength” or “X contributes
to the maintenance of normal bone remodeling (or
increases bone formation or decreases bone resorption)
that increases bone strength” or “X increases bone
strength”.
4. Maintenance or improvement in bone structure
The key role of bone microarchitecture in bone
health was suggested by the classic definition of
osteoporosis adopted in 1993 [19]. Methods for
investigating 3-D bone microarchitecture and bone
strength include in vitro μCT, in vitro μMRI, in vivo
pQCT, and in vivo high-resolution MRI [20]. They aim
to quantify various determinants of bone strength such
as bone geometry, volumetric bone density, micro-
architecture, and properties of the bone matrix [21]. A
food product with an effect on bone microarchitecture
could have the claim: “X improves (or maintains) bone
microarchitecture that could contribute to the normal
structure and function of bones”.
It is considered that the assessment of bone structure
with the tools currently available in man is not sufficiently
validated to be a reliable surrogate of bone strength. For
this reason, animal models are needed to assess the
relationship between changes in bone microarchitecture
induced by the food product and any increase in bone
strength. A food product with an effect on microarchi-
tecture of the human bone and animals studies that show
improvement in bone strength or show the relationship
between change in bone structure induced by the food
product and bone strength could have the claim: “X
improves bone microarchitecture that increases bone
strength” or “X increases bone strength”
5. Maintenance or increase in bone mineral density
Bone strength is determined by many factors,
including bone mass. Bone mass is estimated in clinical
practice by the measurement of BMD. BMD, as
measured by DXA, represents an estimate of the
quantity of mineral (grams of calcium) divided by the
two-dimensional area of the bone [22]. There is a
strong relationship between the risk of fracture and
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BMD but there is a wide overlap in the bone densities
of patients who develop a fracture and those who do
not. Since BMD is only a surrogate marker for bone
strength or fracture risk, and since product-induced
changes in BMD are not clearly associated with
changes in bone strength or fracture risk, an increase
in BMD may not be associated with an increased bone
strength or decreased fracture risk [23]. A food product
with a positive effect on BMD could have the claim: “X
increases BMD. A low BMD is associated with an
increased risk of fracture” or “X maintains BMD. A low
BMD is associated with an increased risk of fracture”.
Animal models are appropriate to determine whether
an increase in BMD associated with a food product is
accompanied by an increase in bone strength. A food
product with a positive effect on BMD, together with
animal studies showing an improvement in bone
strength or showing a relationship between BMD
changes induced by the food product and bone strength,
could have the claim: “X increases (or maintains) BMD
that could reduce the risk of fracture” or “X increases
(or maintains) BMD that increases bone strength” or “X
increases bone strength”.
6. Reduction of the risk of fracture
A reduction of the incidence of fracture is a major
aim of food products beneficial to skeletal health, but
according to the regulation cannot be claimed as such
without mentioning the effect on a risk factor. However,
a reduction in the fracture risk is obviously supportive
for a claim on the reduction of an identified risk factor.
For non-spinal fractures, either femoral (hip) or major
non-vertebral (pelvis, distal femur, proximal tibia, ribs,
proximal humerus forearm, and hip) fractures should be
assessed.
Design of clinical studies
1. Population
The subjects studied should be representative of the
population targeted for the food product. The applicant
should take all necessary precautions to make sure that
the tested population is equivalent to the user popula-
tion with respect of ethnicity, age, physiological status
(such as menopause for example), life habits (such as
exercise) and diet. No densitometric criteria are
required for inclusion. However, the experimental and
the control group must show no significant differences
in term of baseline BMD.
2. Design
The ideal design would be a multicentre randomized
controlled study (RCT). The control could be a placebo,
another active product or nothing, depending on the tested
food. When possible, subjects and/or investigators should
be blinded of the intervention. Treatment and control
groups should be balanced with respect to gender, age,
menopausal status, dietary habits, or underlying diseases.
The GREES panel recognizes that a RCT is not always
possible in practice or from an ethical point of view. Since
the totality of the evidence should be weighed for the
substantiation of a claim, well-designed prospective
cohort studies, case–control studies and/or observational
studies of high quality could be acceptable if accompa-
nied by other data (e.g., animal data, effect on multiple
surrogate endpoints). Cross-over studies design can also
be considered. All the efforts should be made to eliminate
potential confounders.
3. Duration of study
The duration of the trial should be predetermined
and should depend on the outcome. For BMD, duration
of at least 1 year seems necessary. For BTMs, a 3-
month study is the minimum. The primary efficacy
endpoint should be assessed at the end of the
predetermined treatment period in comparison with
the measurement at baseline. Intermediate measure-
ments are also recommended.
4. Statistical analysis
Intention-to-treat analysis should be the primary
method of evaluation. Statistical significance will be
inferred if a P value is equal to or less than 0.05. The
beta risk will be equal to or less than 20%. The sample
size of the study must be calculated prior to the start of
the study. Possible confounding variables should be
managed using appropriate statistical analysis. Within
group (end vs. baseline) and between groups compar-
isons should be made.
5. Diet habit and lifestyle
The control of critical effect modifiers such as
physical activity, synergies with a multitude of other
nutrients and the influence of nutrigenomic relation-
ships must be taken into account.
Intakes of other nutrients or foods, on which the
tested nutrient is dependent, must be optimized. Any
supplementation with other food products known to
have an effect on bone (e.g., calcium and/or vitamin D)
should be consistent within all patient groups.
6. Observance
Observance of food product intake should be
monitored during the study to be able to perform pre-
planned analyses on individuals with high and poor
compliance rates or analyses of dose–response.
7. Safety
All adverse experiences occurring during the course
of clinical trials should be fully documented with
separate analysis of adverse events, dropouts, and
patients who died while being on the study.
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Conclusion
According to the European regulation, the use of nutrition
and health claims shall only be permitted if the food
product has been shown to have a beneficial nutritional or
physiological effect in agreement with the health claim.
However, it must also be pointed out that during the
evaluation of the health claim, besides the characterization
of the effect, important elements will be taken into account,
such as the characterization of the food and the substanti-
ation of the effect. In the field of bone health, claimed
effects are not sufficiently defined and there are no
standardized recommendations for the design and the
methodology of clinical studies needed to reach such health
claims. The consensus reached by the GREES is that the
level of health claim may differ according to the surrogate
endpoint used and on additional animal studies provided to
support the claim. The ideal study design is a RCT but, is
some particular cases, prospective cohort, case-control, or
observational studies can be acceptable. In our opinion,
general principles of the consensus reached are in line with
the principles adopted in the EFSA's published opinions.
This consensus is subject to future modifications when new
validated surrogate markers will be available.
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